Enteroendocrine cell

NRx Pharmaceuticals Announces Progress on Worldwide Commercial Scale Development of ZYESAMI™ (aviptadil)

Retrieved on: 
Tuesday, October 12, 2021

This module will now be used as part of the FDA's rolling review process supporting the New Drug Application for ZYESAMI.

Key Points: 
  • This module will now be used as part of the FDA's rolling review process supporting the New Drug Application for ZYESAMI.
  • NRx awaits a QP Declaration that is required by the EU regulatory authorities for the release of ZYESAMI.
  • The audit was completed in preparation for submission of European Union (EU)-standard ZYESAMI to EU and United Kingdom health regulatory authorities.
  • NRx Pharmaceuticals (NRx) draws upon more than 300 years of collective, scientific, and drug-development experience to bring improved health to patients.

NRx Pharmaceuticals to Work with Cardinal Health to Ensure Efficient Distribution of Potential Therapies

Retrieved on: 
Thursday, August 26, 2021

This partnership creates an efficient and highly flexible logistics and distribution model for NRx.

Key Points: 
  • This partnership creates an efficient and highly flexible logistics and distribution model for NRx.
  • "This partnership creates an efficient and highly flexible logistics and distribution model for NRx.
  • Cardinal Health Specialty Pharmaceutical Distribution will serve as the exclusive distributor for ZYESAMI, providing broad access to hospitals for this needed medicine upon FDA authorization.
  • "Cardinal Health is pleased to ensure that COVID-19 patients get access to treatment in a timely and efficient manner."